Piper Jaffray Companies Analysts Give Alnylam Pharmaceuticals (NASDAQ:ALNY) a $145.00 Price Target

Share on StockTwits

Piper Jaffray Companies set a $145.00 target price on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report released on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

ALNY has been the topic of several other reports. BidaskClub cut Alnylam Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, September 7th. Barclays reissued a buy rating and issued a $125.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th. Morgan Stanley dropped their target price on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an overweight rating on the stock in a research report on Wednesday, August 7th. Cowen dropped their target price on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an outperform rating on the stock in a research report on Wednesday, August 7th. Finally, Stifel Nicolaus set a $116.00 target price on Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, September 3rd. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $116.13.

Shares of Alnylam Pharmaceuticals stock traded up $0.70 during midday trading on Tuesday, reaching $83.87. 2,368 shares of the company’s stock traded hands, compared to its average volume of 668,636. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28. The company has a market cap of $9.30 billion, a PE ratio of -11.05 and a beta of 2.35. The stock has a 50 day moving average of $79.70 and a 200-day moving average of $78.88. Alnylam Pharmaceuticals has a 12 month low of $60.27 and a 12 month high of $99.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The company had revenue of $38.20 million during the quarter, compared to the consensus estimate of $42.24 million. During the same quarter in the prior year, the company earned ($1.61) earnings per share. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post -8.21 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Capital Investment Advisory Services LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $25,000. Price Wealth Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $46,000. US Bancorp DE raised its stake in shares of Alnylam Pharmaceuticals by 70.2% in the second quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 259 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Alnylam Pharmaceuticals by 444.7% in the second quarter. Tower Research Capital LLC TRC now owns 828 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 676 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Alnylam Pharmaceuticals by 107.7% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 837 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 434 shares during the period. 94.26% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: How to Invest in Stocks with Increasing Dividends

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

FedEx  Rating Lowered to Market Perform at BMO Capital Markets
FedEx Rating Lowered to Market Perform at BMO Capital Markets
Heska  Coverage Initiated at Piper Jaffray Companies
Heska Coverage Initiated at Piper Jaffray Companies
Activision Blizzard  PT Raised to $62.00
Activision Blizzard PT Raised to $62.00
Zimmer Biomet  Rating Increased to Buy at Canaccord Genuity
Zimmer Biomet Rating Increased to Buy at Canaccord Genuity
Axsome Therapeutics  Coverage Initiated at William Blair
Axsome Therapeutics Coverage Initiated at William Blair
Vulcan Materials  PT Raised to $165.00
Vulcan Materials PT Raised to $165.00


© 2006-2019 Ticker Report